BioNet Provides Update on Recombinant Acellular Pertussis Vaccine at BioJapan 2014

General Press Releases Thursday October 16, 2014 12:12
YOKOHAMA, Japan--(BUSINESS WIRE)--Oct. 16, 2014
BioNet Recombinant Pertussis vaccine shows safety and immunogenicity in Phase I/II Clinical Study

BioNet-Asia's CEO, Dr Pham Hong Thai provided today an update on the company lead vaccine program in his presentation at BioJapan 2014. Dr Pham said that the current Phase I/II trial in Thailand showed that the vaccine is safe and immunogenic and full results will soon be published in a peer reviewed journal. BioNet Recombinant Acellular Pertussis vaccine will enter clinical Phase II/III in 2015.

Many licensed acellular pertussis vaccines have been associated to a resurgence of pertussis in developed countries. All these vaccines are inactivated by the use of chemicals which denature Pertussis Toxin, the principal antigen present in acellular vaccines. BioNet’s third-generation Pertussis vaccine is using a genetically-inactivated Pertussis Toxin which overcomes the limitations of the chemically-detoxified acellular vaccines. Hence, BioNet Recombinant Pertussis vaccine could potentially be the solution to the re-emergence of pertussis.

About Pertussis

Pertussis is a very contagious respiratory illness caused by Bordetella pertussis. Although the incidence of pertussis has declined through the routine immunization of children, vaccine-induced immunity does not persist long. This phenomenon of “waning immunity” was accentuated by the introduction of acellular pertussis vaccines. There are 16 million pertussis cases worldwide each year, mainly in adolescents and adults. These therefore pass on the disease to infants who have not yet completed their pertussis immunization series, and in whom pertussis is most severe. The resurgence of pertussis calls for the replacement of current acellular vaccines and for new vaccination strategies such as adult booster and maternal immunizations.

About BioNet-Asia

BioNet-Asia is an independent vaccine company with a focus on technological innovation and market access. BioNet has built several strategic alliances fostering vaccine self-reliance leading to the production and supply of billions of doses of vaccines worldwide. In its vaccine manufacturing plant in Thailand, BioNet is developing a broad pipeline of vaccines in R&D and clinical stages, such as Recombinant Acellular Pertussis, CRM197 protein carrier, Dengue and Hepatitis B vaccines. The company has transferred the technology to produce Hib meningitis vaccine which is now commercialized as a pentavalent vaccine in Asia. BioNet is a trusted vaccine partner for product development, technology transfer and global market access.

CONTACT:
BioNet-Asia Co., Ltd.
Mr Supachai Nampornchaisakul, +66-2361-8110
info@bionet-asia.com
www.bionet-asia.com

Latest Press Release

Spencer Stuart Launches New Unit Formed from the Talent-Related Businesses it Acquired from Aon

Spencer Stuart, a leading executive search and leadership advisory firm, today announced the launch of the new business unit formed from the Culture & Engagement, Leadership Assessment & Development and HR & Talent Advisory businesses it...

KBank encourages volunteers to join forces in creating a sustainable society under Tham Di Thai Dai: Lets Do Good Deeds Together Again

KBank never stops doing good deeds, and aims to do even more this year. To help create a happy and sustainable society, the Bank allows its employees to take a day off each year to join the "Tham Di Tham Dai: Let's Do Good Deeds Together Again" program....

Photo Release: CPF Philippines carries on Medical and Dental Mission into the third year.

Engr. Eloy Castillo Eclar, Municipal Mayor of Gerona, the Philippines, presided over the opening ceremony of the Medical and Dental Mission for the third year. The project was initiated by Charoen Pokphand Foods Corporation Philippines (CPF Philippines)...

SaaS Version of Premium Container Carrier Operations Solution ALLEGRO to be a Gamechanger

CyberLogitec, the leading provider of maritime, port/terminal and logistics operations technologies, today announced the new ALLEGRO SaaS, an integrated container carrier operations solution. The solution expands CyberLogitec's comprehensive container...

PHNIX Low Temperature Sludge Dryer System - A Leading Solution on Wet Sludge Drying in Asia

A Sludge Dryer System, as a new self-developed sludge drying product by PHNIX -- a leading manufacturer of heat pump and environmental protection equipment in China, has been well received by users in some countries. The newly developed environmentally...

Related Topics